CytomX Therapeutics

ABOUT CYTOMX

CytomX is a clinical-stage biopharmaceutical company focused on the goal of reinventing antibody therapeutics for the treatment of cancer through the development of a new generation of anti-cancer therapies called Probody® therapeutics. Probody therapeutics are designed to exploit the unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity, limiting activity in healthy tissues to potentially solve the toxicity challenges associated with today's treatment options. We and our partners currently have four clinical-stage Probody programs in development.



The "masking" peptide is designed to limit the ability of Probody therapeutics to bind to healthy tissue—thereby helping to minimize toxicities.



In the tumor environment, protease enzymes are expected to cleave the substrate, removing the "mask" and activating the Probody therapeutic to bind to its target on cancer cells.

Our innovative pipeline focuses on a diverse array of next-generation therapies that include Probody cancer immunotherapies, directed against clinically validated targets such as CTLA-4, and novel, first-in-class Probody drug conjugates (PDCs) directed against difficult-to-drug targets such as CD166 and CD71. Additionally, the company has emerging applications for T cell engaging bispecific antibodies and chimeric antigen receptor (CAR) T cell therapies.

PROBODY THERAPEUTICS HAVE THE POTENTIAL TO:

- Overcome toxicity challenges associated with many current cancer treatments
- Enhance the efficacy and safety of combination regimens used to treat cancer
- Expand the universe of possible drug targets previously considered inaccessible to traditional antibody drug conjugates
- Offer new, more powerful treatment options—especially for patients underserved by current therapies

PRODUCT CANDIDATE	INDICATION	DISCOVERY	LEAD OPTIMIZATION	IND-ENABLING	PHASE 1	PHASE 2	PARTNER
CX-2009*	ER/PR Positive, HER2 Negative Breast Cancer	CD166 Probody drug conjugate					CytomX Therapeutics
CX-072 + CX-2009	TNBC	Initiation in 2H 2020					CytomX Therapeutics
BMS-986249	Metastatic Melanoma	CTLA-4 Probody immunotherapy					Bristol Myers Squibb
CX-2029†	Solid Tumors	CD71 Probody drug conjugate					abbvie, CytomX Therapeutics
BMS-986288	Solid Tumors	CTLA-4 NF Probody immunotherapy					Bristol Myers Squibb
CX-904	TBA	EGFR-CD3 T cell bispecific					AMGEN, CytomX Therapeutics
Preclinical EpCAM-PDC	TBA	EpCAM Probody drug conjugate					CytomX Therapeutics
Preclinical CD3-TCB	TBA	CD3 TCB					astellas, CytomX Therapeutics, AMGEN
Additional PDCs, IO, TCBs	TBA						CytomX Therapeutics

*The COVID-19 pandemic has CytomX temporarily pausing enrollment and conduct of the CX-2009 clinical program.
†CytomX and AbbVie are finalizing next steps for the advancement of CX-2029 into Phase 2 expansion cohorts.

Wholly Owned Partnered

CD166: activated leukocyte cell adhesion molecule
CD3: cluster of differentiation 3
CD71: transferrin receptor
CTLA-4: cytotoxic T-lymphocyte-associated protein 4
EGFR: epidermal growth factor receptor
EpCAM: epithelial cell adhesion molecule
IND: investigational new drug application
IO: immunotherapy
NF: non-fucosylated
PDC: Probody drug conjugate
TCB: T cell engaging bispecific
TNBC: triple negative breast cancer

Last updated as of July 2020

CytomX THERAPEUTICS

LEAD CANDIDATES

CX-2009 (CD166-DIRECTED PROBODY DRUG CONJUGATE)

CX-2009 is a wholly owned Probody drug conjugate directed against CD166, also known as ALCAM, for the treatment of cancer. CD166 is a molecule widely and highly expressed on solid tumor cells, as well as on normal tissues, and therefore has been considered undruggable. CX-2009 is conjugated with DM4, a highly potent cytotoxic drug. Data presented in selected tumor types showed CX-2009 to be well tolerated at doses up to 7 mg/kg with encouraging clinical activity observed in patients with breast cancer. CytomX is evaluating CX-2009 as a monotherapy in patients with hormone receptor (ER, PR) positive, HER2 negative breast cancer.

CX-072 (PD-L1-TARGETING PROBODY THERAPEUTIC)

CX-072 is a wholly owned PD-L1-targeting Probody therapeutic for the treatment of cancer. Clinical data presented showed that CX-072 demonstrated favorable tolerability and anti-tumor activity profiles, while reducing activation of the immune system outside the tumor. In addition, data presented confirmed that CX-072 is unmasked, activated, and has biological activity in patient tumors while remaining predominantly masked and intact in circulation. Following a recent program and portfolio prioritization, CytomX terminated the Phase 2 trial of CX-072 in combination with Yervoy® (ipilimumab) in melanoma allowing CytomX to focus on its potential first-in-class assets, including the combination of CX-072 and CX-2009.

BMS-986249 (CTLA-4-DIRECTED PROBODY THERAPEUTIC)

Bristol Myers Squibb (BMS) has initiated a Phase 2 randomized 5-arm cohort expansion of its ongoing first-in-human Phase 1/2a clinical trial to evaluate a CTLA-4-directed Probody therapeutic, BMS-986249, a Probody version of the anti-CTLA-4 antibody Yervoy® (ipilimumab), alone or in combination with Opdivo® (nivolumab) in patients with metastatic melanoma.

CX-2029 (CD71-DIRECTED PROBODY DRUG CONJUGATE)

CytomX and AbbVie are co-developing CX-2029, a Probody drug conjugate directed against CD71. CD71, also known as the transferrin receptor, is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues and considered an undruggable target. CX-2029 is conjugated with MMAE, a highly toxic chemotherapeutic agent. CytomX is evaluating CX-2029 in a Phase 1/2 clinical trial as monotherapy. Initial Phase 1 data presented validates CD71 as a first-in-class oncology target with encouraging clinical activity observed. CytomX is preparing to advance CX-2029 into 4 dose-expansion cohort trials in patients with head and neck cancer, squamous non-small cell lung cancer, esophageal carcinoma, and diffuse large B cell lymphoma.

BMS-986288 (CTLA-4 PROBODY THERAPEUTIC)

Bristol Myers Squibb has initiated the dose escalation phase of a Phase 1/2a clinical study of a second anti-CTLA-4 Probody, BMS-986288, based on a nonfucosylated version of Yervoy® (ipilimumab), administered as monotherapy and in combination with Opdivo® (nivolumab) in patients with selected advanced solid tumors.

CX-904 (EGFR-Directed Probody Therapeutic T Cell Engaging Bispecific)

CytomX and Amgen have advanced CX-904, a leading Probody T Cell Engaging Bispecific (TCB) candidate against EGFR, into IND-enabling studies. CytomX is responsible for IND filing, anticipated for late 2021, and early stage development.

ANALYSTS

Ticker Symbol:
NASDAQ:CTMX

Barclays
Peter Lawson, D. Phil. (Oxon)

Citi
Mohit Bansal

Cowen & Company
Boris Peaker, Ph.D.

Goldman Sachs & Co. LLC
Terence Flynn, Ph.D.

Guggenheim Securities, LLC
Etzer Darout, Ph.D.

H.C. Wainwright & Co.
Raghuram Selvaraju, Ph.D.

Jefferies LLC
Biren Amin

Mizuho Securities USA
Mara Goldstein

Nomura Instinet
Christopher N. Marai, Ph.D.

Piper | Sandler
Joseph Cantanzaro, Ph.D.

Wedbush Securities
Robert Driscoll

KEY FACTS

151 Oyster Point Blvd
Suite 400
South San Francisco, CA
94080

Offices: 650.515.3185
Fax: 650.351.0353

www.cytomx.com

Last updated as of July 2020

CytomX Therapeutics

PARTNERSHIPS

CytomX actively seeks strategic partnerships to advance the next generation of highly targeted antibody therapies. These alliances allow us to broaden the application of our Probody platform and advance the most promising drug candidates to patients.

In April 2016, CytomX entered into a strategic collaboration with AbbVie Inc. to co-develop and co-commercialize PDCs. Under the terms of the agreement, CytomX and AbbVie will co-develop a PDC against CD71, with CytomX leading pre-clinical and early clinical development. AbbVie will lead later development and commercialization, with global late-stage development costs shared between the two companies. AbbVie will lead global commercial activities with CytomX eligible to receive a profit share in the U.S. and tiered double-digit royalties on net product sales outside of the U.S. CytomX retains an option to co-promote in the U.S. AbbVie also receives exclusive worldwide rights to develop and commercialize PDCs against up to two additional, undisclosed oncology targets. In July 2019, AbbVie selected the second of two targets.

In October 2017, CytomX entered into a strategic immuno-oncology collaboration with Amgen to co-develop T cell engaging bispecific therapeutics. The companies are co-developing a CytomX Probody T cell engaging bispecific against EGFR, a highly validated oncology target expressed on multiple human cancer types, with CytomX leading early development. Amgen will lead later development and commercialization with global late-stage development costs shared between the two companies. CytomX is eligible to receive development, regulatory and commercial milestones for the EGFR program. Amgen will lead global commercial activities with CytomX able to opt into a profit share in the U.S. and receive tiered, double-digit royalties on net product sales outside of the U.S.

Amgen also receives exclusive worldwide rights to develop and commercialize up to three additional, undisclosed targets. Should Amgen ultimately pursue all of these targets, CytomX will be eligible to receive additional upfront and milestone payments and high single-digit to mid double-digit royalty payments on any resulting products. CytomX also receives the rights from Amgen to an undisclosed preclinical T cell engaging bispecific program. Amgen is eligible to receive milestones and royalty payments on any resulting products from this CytomX program.

In May 2014, CytomX entered into a worldwide strategic collaboration with Bristol Myers Squibb to develop and commercialize novel therapies using CytomX's Probody platform. The collaboration was expanded in March 2017. Bristol Myers Squibb has initiated a randomized Phase 2 study of BMS-986249, a CTLA-4 Probody therapeutic candidate, in combination with Opdivo® (nivolumab) in patients with metastatic melanoma. Bristol Myers Squibb also initiated the dose escalation phase of a Phase 1/2a clinical trial of a second anti-CTLA-4 Probody, BMS-986288, a nonfucosylated version of Yervoy® (ipilimumab), administered as monotherapy and in combination with Opdivo® (nivolumab) in patients with selected advanced solid tumors.

In March 2020, CytomX entered into a strategic collaboration with Astellas to co-develop T cell engaging bispecific therapeutics. The companies are co-developing CytomX Probody T cell engaging bispecifics against the clinically validated oncology target cluster of differentiation 3 (CD3). CytomX and Astellas will collaborate on several initial programs with CytomX leading research and discovery activities, up to clinical candidate selection. Astellas will lead and fund preclinical and clinical development and commercialization activities with CytomX eligible to receive tiered high-single digits to mid-teens royalties on net product sales outside of the U.S. For a specified number of targets, prior to the initiation of the first pivotal clinical trial for a product directed toward such target, CytomX may exercise an option to co-fund a pre-determined portion of clinical development costs. For these products, CytomX is eligible to receive a pre-specified portion of profits in the U.S. and tiered low-double digit to mid-teen percentage royalties on net sales outside of the U.S. CytomX may later elect to co-commercialize the products directed toward such targets in the U.S.

We are advancing a deep oncology pipeline of Probody therapeutics by blazing our own trail and in partnership with some of the world's leading biopharmaceutical companies.

The breadth of the cancer targets and the cancer treatment approaches to which Probody technology may be applied has spurred value creating collaborations with industry leaders while CytomX retains full rights to its lead programs, CX-072 and CX-2009.